Link between Semaglutide and Panic Attacks: Comparing Reports Over Time to Check for Bias in Drug Safety Data

An evaluation of the semaglutide-panic attack signal was conducted using data from the FDA Adverse Event Reporting System.

• Confounding by indication and notoriety bias may influence the interpretation of adverse event signals.
• The signal associated with semaglutide and panic attacks requires careful scrutiny to understand its validity.
• An evidence-triangulation framework was applied, integrating findings from both randomized and observational studies.

Simplified